Author Archives: Marisa Wexler, MS

Phase 2 trial of GLPG3667 for SLE now recruiting patients in US

Galapagos officially has launched a Phase 2 clinical trial that will test its oral therapy GLPG3667 — designed to ease disease severity in people with systemic lupus erythematosus (SLE) — at a half dozen sites in the U.S. The first participant has been randomized, or assigned to a treatment…

Phase 3 trials of ianalumab for SLE, lupus nephritis now enrolling

Three new Phase 3 clinical trials testing the experimental therapy ianalumab in people with systemic lupus erythematosus (SLE) and lupus nephritis are now recruiting patients. All three trials are being sponsored by Novartis, the company developing ianalumab. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance,…

Lupkynis approved in Switzerland to treat adults with lupus nephritis

Lupkynis (voclosporin) is now approved in Switzerland to treat adults with active lupus nephritis, a complication of lupus characterized by kidney damage and inflammation. The approval specifically covers the treatment, given along immunosuppressants, for adults with active class 3, 4, and 5 lupus nephritis — three subtypes of the…

Lupus community aims to improve visibility this Awareness Month

The Lupus Foundation of America (LFA) is calling on the community to help increase visibility and promote education about the autoimmune disease throughout the month of May — thereby marking Lupus Awareness Month. “All too often people with lupus hear that they don’t ‘look’ sick. This is why…

Upadacitinib headed to Phase 3 testing in SLE

Treatment with upadacitinib led to a significant reduction in disease activity for people with moderate-to-severe systemic lupus erythematosus (SLE) in a Phase 2 clinical trial, according to top-line results announced by its developer, AbbVie. Based on these positive results, AbbVie now is planning to advance upadacitinib to Phase 3 clinical…